ALK and non-small cell lung carcinoma: In this study, we found that sequential regimens of EGFR‐ or FGFR‐TKIs plus alectinib followed by GPX4 inhibitors alternately every 1 or 2 weeks was successful in reducing viable cell numbers with an efficacy comparable to that of parallel concurrent triple combination treatment in both of two types of ALK+ NSCLC cells (Figs 6H and 8H).